

## Data Sharing Statement

<b>Article Info</b>	<a href="https://dx.doi.org/10.21037/tlcr-24-795">https://dx.doi.org/10.21037/tlcr-24-795</a>	
<b>Item</b>	<b>Question</b>	<b>Authors' Response (place "-" if not applicable)</b>
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	Both efficacy and safety data are available to be shared.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Study protocol, statistical analysis plan, informed consent form, and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Three years within the publication date.
7	To whom will you share the data?	Medical oncologists who are interested in immunotherapy.
8	For what type of analysis or purpose?	For analysis to increase immunotherapy efficacy and reduce side effects.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: zhangweihong@tjmuch.com
10	Any other restrictions?	NO.